FDA rejects Regenxbio’s rare-disease gene therapy Agency raised questions about the surrogate biomarker used to predict clinical benefit By Adam FeuersteinFeb. 9, 2026 Senior Writer, Biotech

https://www.statnews.com/2026/02/09/fda-rejects-regenxbio-rare-disease-gene-therapy/